+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Hepatitis C Drugs Market 2019-2023 - Product Image

Global Hepatitis C Drugs Market 2019-2023

  • ID: 4747507
  • Report
  • January 2019
  • Region: Global
  • 113 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Gilead
  • Merck
  • MORE
The increasing number of voluntary licensing agreements to drive market growth. Voluntary licensing helps in improving access to essential medicines. Under the voluntary licensing agreement, patent holders license others to manufacture, import, and/or distribute their patented drugs. Voluntary licenses enable the development of generic versions of drugs, which increases the affordability and access to the patients. The analysts have predicted that the hepatitis C drugs market to register a revenue of around USD 5.7 billion by 2023.

Market Overview

Increasing demand for direct-acting antiviral

Direct-acting antiviral drugs have emerged as a curative option for patients with hepatitis C. These drugs act and block specific steps in the lifecycle of the HCV. They are known to target the specific nonstructural proteins of the virus that results in the disruption of viral replication. Thus, they show comparatively fewer side effects than the interferons, which were employed until the advent of direct-acting antiviral drugs.

Side effects of available drugs

The interferons indicated for the treatment of hepatitis C are known to be associated with harmful side effects such as excessive fatigue, headache, weight loss, alopecia, autoimmune disorders, high blood pressure, slowed growth in children, changes in vision, and malfunctioning of the lungs, liver, and pancreas. Due to these side effects, the interferon therapy is replaced by direct-acting antivirals at present.

For the detailed list of factors that will drive and challenge the growth of the hepatitis C drugs market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Gilead and Merck, the competitive environment is quite intense. Factors such as the increasing demand for direct-acting antiviral and the increasing number of voluntary licensing agreements, will provide considerable growth opportunities to hepatitis C drugs manufactures. AbbVie, Bristol-Myers Squibb, F. Hoffmann-La Roche, Gilead, and Merck are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Gilead
  • Merck
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Combination therapy - Market size and forecast 2018-2023
  • Monotherapy - Market size and forecast 2018-2023
  • Market opportunity by product
PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE
  • Acute hepatitis C
  • Chronic hepatitis C
PART 10: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Gilead
  • Merck
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Years in consideration
Exhibit 02: Global infectious disease treatment market
Exhibit 03: Segments of global infectious disease treatment market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Molecules in Phase III and Phase II stages of evaluation for hepatitis C treatment
Exhibit 07: Market definition - Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2018
Exhibit 19: Product - Market share 2018-2023 (%)
Exhibit 20: Comparison by product
Exhibit 21: Combination therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Combination therapy - Year-over-year growth 2019-2023 (%)
Exhibit 23: Monotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Monotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by product
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 31: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 33: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 35: Key leading countries
Exhibit 36: Market opportunity
Exhibit 37: Decision framework
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: AbbVie - Vendor overview
Exhibit 45: AbbVie - Business segments
Exhibit 46: AbbVie - Organizational developments
Exhibit 47: AbbVie - Geographic focus
Exhibit 48: AbbVie - Key offerings
Exhibit 49: Bristol-Myers Squibb - Vendor overview
Exhibit 50: Bristol-Myers Squibb - Business segments
Exhibit 51: Bristol-Myers Squibb - Organizational developments
Exhibit 52: Bristol-Myers Squibb - Geographic focus
Exhibit 53: Bristol-Myers Squibb - Key offerings
Exhibit 54: F. Hoffmann-La Roche - Vendor overview
Exhibit 55: F. Hoffmann-La Roche - Business segments
Exhibit 56: F. Hoffmann-La Roche - Organizational developments
Exhibit 57: F. Hoffmann-La Roche - Geographic focus
Exhibit 58: F. Hoffmann-La Roche - Segment focus
Exhibit 59: F. Hoffmann-La Roche - Key offerings
Exhibit 60: Gilead - Vendor overview
Exhibit 61: Gilead - Business segments
Exhibit 62: Gilead - Organizational developments
Exhibit 63: Gilead - Geographic focus
Exhibit 64: Gilead - Key offerings
Exhibit 65: Merck - Vendor overview
Exhibit 66: Merck - Business segments
Exhibit 67: Merck - Organizational developments
Exhibit 68: Merck - Geographic focus
Exhibit 69: Merck - Segment focus
Exhibit 70: Merck - Key offerings
Exhibit 71: Validation techniques employed for market sizing
Exhibit 72: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AbbVie
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Gilead
  • Merck
  • MORE
Global Hepatitis C Drugs Market 2019-2023

The author recognizes the following companies as the key players in the global hepatitis C drugs market: AbbVie, Bristol-Myers Squibb, F. Hoffmann-La Roche, Gilead, and Merck.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing number of voluntary licensing agreements.”

According to the report, one of the major drivers for this market is the increasing demand for direct-acting antiviral.

Further, the report states that one of the major factors hindering the growth of this market is the side effects of available drugs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AbbVie
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Gilead
  • Merck
Note: Product cover images may vary from those shown
Adroll
adroll